X4 PHARMACEUTICALS INC's ticker is XFOR and the CUSIP is 98420X103. A total of 54 filers reported holding X4 PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is 1.98 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $9 | -90.4% | 10,092 | -89.4% | 0.00% | – |
| Q4 2022 | $94 | -100.0% | 94,794 | -60.9% | 0.00% | -100.0% |
| Q3 2022 | $414,000 | +98.1% | 242,194 | +12.0% | 0.00% | – |
| Q2 2022 | $209,000 | -31.0% | 216,194 | +24.9% | 0.00% | – |
| Q1 2022 | $303,000 | -3.5% | 173,094 | +26.1% | 0.00% | – |
| Q4 2021 | $314,000 | -50.7% | 137,294 | +14.0% | 0.00% | -100.0% |
| Q3 2021 | $637,000 | -25.1% | 120,394 | -7.9% | 0.00% | 0.0% |
| Q2 2021 | $850,000 | -36.8% | 130,694 | -16.2% | 0.00% | -50.0% |
| Q1 2021 | $1,344,000 | +28.7% | 156,044 | -3.9% | 0.00% | +100.0% |
| Q4 2020 | $1,044,000 | -1.1% | 162,424 | +4.1% | 0.00% | 0.0% |
| Q3 2020 | $1,056,000 | +10.1% | 156,044 | +51.7% | 0.00% | 0.0% |
| Q2 2020 | $959,000 | +78.3% | 102,844 | +91.0% | 0.00% | 0.0% |
| Q1 2020 | $538,000 | -20.6% | 53,844 | -15.0% | 0.00% | 0.0% |
| Q4 2019 | $678,000 | – | 63,344 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 12,202,510 | $10,616 | 1.33% |
| Tri Locum Partners LP | 3,878,484 | $3,374,281 | 1.03% |
| Lynwood Capital Management Inc. | 900,000 | $783,000 | 0.71% |
| NEA Management Company, LLC | 11,736,793 | $10,211,010 | 0.71% |
| Parkman Healthcare Partners LLC | 2,797,147 | $2,433,518 | 0.53% |
| SCOGGIN MANAGEMENT LP | 484,796 | $567,025 | 0.33% |
| New Leaf Venture Partners, L.L.C. | 335,000 | $291,450 | 0.24% |
| Ghost Tree Capital, LLC | 850,000 | $740,000 | 0.22% |
| Perceptive Advisors | 4,545,454 | $3,954,545 | 0.12% |
| Orbimed Advisors | 5,817,726 | $5,061,422 | 0.10% |